Dr. Toru Miyazaki—the pioneer behind AIM protein research—will be officially beginning clinical trials for a new AIM drug aimed at treating CKD in cats. Over 500 cat owners have already signed up for the trial, underscoring the community’s hope for improved feline kidney care.
The trials are expected to wrap up this year, with regulatory approval applications in Japan expected to follow next year. This study is seen as a major first step toward making this promising treatment accessible to cats around the globe.
In response to the news, Greycoat Research will be conducting studies on potential synergistic effects between the new AIM drug and its Dr. Toru Protocol, Intensive Protocol, and Probiotics Protocol supplements. The company believes these studies will help raise the standard of care for cats suffering from CKD.